LGC Axolabs mission: To be the single organization to deliver best solutions for oligonucleotide development, ranging from lead ID, over all clinical stages, up to commercial supply.

LGC Axolabs Nucleic Acid Therapeutics unit offers a unique services portfolio for the development of nucleic acid therapeutics and nucleic acid-based medicines. LGC is dedicated to highest scientific standards fostered by world class expertise and capabilities in oligonucleotide (bio)-analytics, clinical trial support, and cGMP manufacture.